This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Michele Pagano | |
|---|---|
| Name | Michele Pagano |
| Fields | Cell biology; Biochemistry; Oncology |
| Known for | Ubiquitin-mediated proteolysis; Cyclin-dependent kinases; Cell cycle regulation |
Michele Pagano is an Italian-born biochemist and cell biologist known for contributions to the molecular understanding of cell cycle control and ubiquitin-mediated proteolysis. He has led research groups that elucidated mechanisms by which E3 ubiquitin ligases regulate cyclin-dependent kinases, signaling pathways in cancer, and proteostasis in eukaryotic cells. Pagano’s work bridges molecular genetics, protein biochemistry, and translational oncology, influencing studies in cell cycle checkpoints, ubiquitin ligase complexes, and targeted cancer therapeutics.
Pagano was born in Italy and trained in the European and American research environments that shaped late 20th-century molecular biology. He undertook undergraduate studies and doctoral training that connected him to institutions with strong traditions in molecular genetics, protein chemistry, and cancer research. During his postdoctoral period he worked in laboratories focused on signal transduction and cell cycle control, collaborating with investigators involved in studies associated with Max Planck Society, European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, and university hospitals in the United States and Europe. Early mentors included principal investigators who had links to research networks around National Institutes of Health, University of Cambridge, Harvard Medical School, and other centers influential in cell cycle and ubiquitin research.
Pagano established an independent laboratory that concentrated on the regulation of cyclin-dependent kinases by ubiquitin ligases and the role of proteolysis in cell proliferation and tumorigenesis. His group characterized components of multi-subunit ubiquitin ligases, interacting with work on SCF complex, F-box proteins, and the broader ubiquitin–proteasome system studied by groups at Rockefeller University, Massachusetts Institute of Technology, and Stanford University. Collaborations and scientific exchanges connected his lab to investigators at National Cancer Institute, Memorial Sloan Kettering Cancer Center, Dana–Farber Cancer Institute, and European cancer research centers.
Throughout his career Pagano has combined biochemical reconstitution, genetic screens, and cell-based assays to define substrate recognition by E3 ligases and the consequences for cell cycle transitions, DNA replication, and genomic stability. His laboratory’s work intersected with studies on oncogenes and tumor suppressors investigated at MD Anderson Cancer Center, Johns Hopkins University, Cold Spring Harbor Laboratory, and other institutions exploring mechanisms underlying breast cancer, colorectal cancer, and hematologic malignancies. Pagano’s research trajectory includes mentoring postdoctoral scholars who later joined faculties at universities such as University of Oxford, University College London, Yale University, and University of California, San Francisco.
Pagano’s major discoveries clarified how F-box proteins within the SCF (Skp1-Cullin-F-box) complex target specific cell cycle regulators for ubiquitin-dependent degradation. His lab identified and characterized F-box proteins that recognize phosphorylated substrates, elucidating links between phosphorylation by cyclin-dependent kinase complexes and proteolysis. These findings connected to broader themes investigated by researchers at EMBL, Scripps Research, and Institut Curie on how post-translational modifications determine protein stability.
He contributed to defining the role of specific ubiquitin ligase adaptors in the turnover of cyclins and cyclin inhibitors, advancing understanding of how deregulation of E3 ligases promotes oncogenic transformation in contexts studied at Memorial Sloan Kettering Cancer Center and Dana–Farber Cancer Institute. Pagano’s group uncovered mechanisms by which degradation pathways control DNA replication licensing factors and checkpoint proteins, intersecting with investigations into ATR, ATM, and p53 signaling conducted at Cold Spring Harbor Laboratory and NIH-affiliated labs.
His work also influenced the development of therapeutic strategies targeting ubiquitin–proteasome components and E3 ligases, aligning with drug-discovery programs at Genentech, Novartis, Pfizer, and biotechnology firms exploring proteolysis-targeting chimeras (PROTACs) pioneered in collaborations with academic and industry partners. Pagano’s mechanistic insights informed biomarker studies and preclinical models relevant to targeted therapies for cancers harboring cell cycle pathway alterations.
Pagano has received recognition from international scientific organizations and academies for contributions to cell biology and cancer research. Honors include awards and lectureships associated with societies and institutions such as the European Molecular Biology Organization, American Association for Cancer Research, American Society for Biochemistry and Molecular Biology, and national academies linking to Accademia dei Lincei and other scholarly bodies. He has been invited to present keynote addresses at symposia hosted by venues including Cold Spring Harbor Laboratory, EMBO, Gordon Research Conferences, and major oncology meetings.
- Pagano M., et al. Studies on F-box proteins and substrate recognition in the SCF complex. Journal articles in journals parallel to Nature, Science, Cell, and EMBO Journal documented mechanistic advances in ubiquitin-mediated regulation. - Pagano M., et al. Investigations into cyclin degradation and CDK regulation with implications reported in publications associated with Proceedings of the National Academy of Sciences and Molecular Cell. - Pagano M., et al. Works on DNA replication licensing and checkpoint integration cited alongside contributions in Nature Cell Biology and Cancer Research. - Pagano M., et al. Reviews synthesizing ubiquitin–proteasome biology and therapeutic prospects featured in venues like Trends in Cell Biology and Annual Review of Biochemistry.
Category:Cell biologists Category:Biochemists